Skip to main content

Table 7 Pharmacokinetics (Study 1 + Study 2)

From: Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients

 

Study 1

Study 2

Adults IM (1A + 1B)

1C

1D

2A

2Bb

n

64c

30

14

8

8

Cmax or Cmax,ss (ng/mL)a

355 ± 51

390 ± 55

332 ± 91

862 ± 45

477 ± 91

AUC or AUC0-24,ss (ng.h/mL)a

674 ± 109

480 ± 92

479 ± 111

1470 ± 375

1400 ± 270

  1. Pharmacokinetic parameters: AUC 0-24ss: AUC24 at steady state; Cmaxss: Cmax at steady state
  2. aMean and SD
  3. bFor the twice daily treatment group, the AUC0-24 at steady state was the AUC0-12 at steady state multiplied by 2
  4. cPooling patient data after 1 day and 3 day treatment since no accumulation of exposure is observed after repeated dosing
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us